CTXR vs. RPTX, EBS, KPTI, GLYC, RLMD, INCR, PDSB, COYA, NVCT, and ADAG
Should you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include Repare Therapeutics (RPTX), Emergent BioSolutions (EBS), Karyopharm Therapeutics (KPTI), GlycoMimetics (GLYC), Relmada Therapeutics (RLMD), InterCure (INCR), PDS Biotechnology (PDSB), Coya Therapeutics (COYA), Nuvectis Pharma (NVCT), and Adagene (ADAG). These companies are all part of the "pharmaceutical preparations" industry.
Repare Therapeutics (NASDAQ:RPTX) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, community ranking, institutional ownership, dividends, risk, profitability, media sentiment and valuation.
Repare Therapeutics has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500.
85.1% of Repare Therapeutics shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 28.5% of Repare Therapeutics shares are held by insiders. Comparatively, 15.0% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Citius Pharmaceuticals received 172 more outperform votes than Repare Therapeutics when rated by MarketBeat users. Likewise, 62.05% of users gave Citius Pharmaceuticals an outperform vote while only 60.71% of users gave Repare Therapeutics an outperform vote.
Citius Pharmaceuticals has a net margin of 0.00% compared to Citius Pharmaceuticals' net margin of -183.43%. Citius Pharmaceuticals' return on equity of -39.82% beat Repare Therapeutics' return on equity.
In the previous week, Repare Therapeutics and Repare Therapeutics both had 2 articles in the media. Repare Therapeutics' average media sentiment score of 0.49 beat Citius Pharmaceuticals' score of 0.00 indicating that Citius Pharmaceuticals is being referred to more favorably in the news media.
Repare Therapeutics presently has a consensus price target of $17.33, suggesting a potential upside of 396.66%. Citius Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 467.38%. Given Repare Therapeutics' higher possible upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Repare Therapeutics.
Citius Pharmaceuticals has lower revenue, but higher earnings than Repare Therapeutics. Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Citius Pharmaceuticals beats Repare Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Citius Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Citius Pharmaceuticals Competitors List
Related Companies and Tools
